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ing explored. An emerging molecular target for lung
cancer is the signaling molecule Akt as it is frequently
activated in lung cancer. Akt is activated by a number of
growth factor receptors and mediates processes such as
proliferation, survival, migration, and metabolism. Three
Akt isoforms (Akt1-3) exist in mammals and it remains
unclear whether each isoform has distinct functions. To
evaluate the function of Akt isoforms in lung cancer, a
transgenic mouse model (SPC-IGFIR) where lung tumors
were induced by elevated expression of IGF-IR and
subsequent activation of Akt was used. SPC-IGFIR mice
were mated with Akt1-/- or Akt2-/- mice to produce SPC-
IGFIR mice lacking either Akt1 or Akt2. Lung tumori-
genesis was suppressed in SPC-IGFIR/Akt1-/- mice and
enhanced in SPC-IGFIR/Akt2-/- mice. Lung tumor cells in
SPC-IGFIR/Akt2-/- mice appeared to inﬁlitrate the lungs
to a greater extend than either SPC-IGFIR or SPC-IGFIR/
Akt1-/- tumor cells which had a more nodular appear-
ance. RNA sequencing revealed a number of genes and
transcripts differentially expressed in the SPC-IGFIR/
Akt2-/- lung tumors and several of these genes have been
implicated in human NSCLC. Using 2 human NCSLC cell
lines it was determined that an AKT1 selective inhibitor
impaired cell survival more than an AKT2 inhibitor or a
pan-AKT inhibitor. These results suggest that inhibition
of Akt1 may represent a therapeutic strategy for lung
cancer.
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Purpose: Although long-term survival rates for early
stage lung cancer are high, most patients are diagnosed
with advanced stage disease. The National Lung
Screening Trial demonstrated a survival beneﬁt with
annual low-dose chest CT (LDCT) in patients at high risk,
despite a false positive rate of 96%. Most attempts atdevelopment of blood-based early detection for lung
cancer employ panels of several biomarkers, which are
susceptible to overﬁtting and poor reproducibility on
new samples. We hypothesized that a single biomarker-
based approach would be more effective.
Methods: Whole blood was collected in PAXgene tubes
from 289 patients under IRB-approved protocols at four
institutions. This included 231 retrospective specimens
and 58 specimens collected prospectively. We collected
smoking history, cancer diagnosis, age and gender for all
patients. Due to the use of a single marker and low risk
of overﬁtting, the training set consisted of only 29 pa-
tients. The validation set consisted of 133 non-small cell
lung cancer, 14 small cell lung cancer and 113 cancer-
free patients. A total of 11 patient cohorts were created
based on combination of cancer histology and smoking
history. RNA was extracted, and the expression of formyl
peptide receptor 1 (FPR1) and a reference gene were
quantiﬁed by an automated one-step Taqman RT-PCR
assay.
Results: In the validation set, elevated levels of FPR1
mRNA in whole blood demonstrated a sensitivity of 55%
and a speciﬁcity of 87% for lung cancer detection.
Among prospectively collected specimens, FPR1 mRNA
had a sensitivity of 68% and speciﬁcity of 89%. The
sensitivity of prospective samples was signiﬁcantly
higher than retrospective samples (p¼0.018) while the
speciﬁcity was unchanged. We observed that longer
times between collection and refrigeration/freezing of
samples tended to yield negative results. This time was
much shorter on prospective samples, and this likely
explains the increased sensitivity. No signiﬁcant differ-
ence in sensitivity was observed based on histology
(including small cell vs. non-small cell) or cancer stage.
Results from patients with benign nodules were similar
to healthy volunteers. We used multiple data mining
techniques and found no meaningful relationship be-
tween our test results and any clinical characteristic
other than lung cancer diagnosis, including age, smoking
history, and gender.
Discussion: FPR1 mRNA levels in whole blood can iden-
tify the presence of lung cancer with high accuracy. A
single-marker test is less prone to overﬁtting of datawhen
compared to amulti-marker test created through complex
data mining algorithms, and thus is more likely to be
reproducible. The use of a training/validation set strategy
further increases likelihood that results will be repro-
duced in follow-on studies. Using FPR1 as a reﬂex test for
suspicious lung cancer screening CT scans may have the
potential to increase the positive predictive value (PPV).
Future planned studies will explore the source of this
biomarker and evaluate its effectiveness in augmenting CT
scans for patients undergoing lung cancer screening.
